Targeting the Second Transferrin Receptor as Emerging Therapeutic Option for β-Thalassemia Major

Hemasphere. 2022 Oct 28;6(11):e799. doi: 10.1097/HS9.0000000000000799. eCollection 2022 Nov.

Authors

Francesca Vinchi^{1

2}, Muhammad Shahzad Ali¹

Affiliations

¹ Iron Research Laboratory, Lindsley Kimball Research Institute, New York Blood Center, New York, NY, USA.
² Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.

No abstract available

Publication types

Editorial